Consistent with these reports, inhibition of SREBP1, either directly or through upstream regulators, has been shown to reduce TNBC cell viability, impair tumor growth, and enhance the effectiveness of existing chemotherapies [94]. This evidence concerns the gene SREBF1 and neoplasm.